Project Grant R37CA306829
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $684K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- Federal Grant Award Summary William Beaumont Hospital received a $498,372 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop a novel multi-approach dynamic Spot Scanning Proton Arc (SPARC) optimization framework. Awarded on September 1, 2025, with completion targeted for August 31, 2029, this project addresses critical clinical challenges in proton therapy delivery for cancer patients, particularly those with head and neck...
- Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...
- Federal Grant Award Summary The National Cancer Institute awarded a $219,024 Project Grant to The University of Texas Health Science Center at Tyler on July 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop CSP7, a caveolin-1 scaffolding domain peptide, as a therapeutic intervention to mitigate radiation-induced lung injury and pulmonary fibrosis. The grant supports research demonstrating that CSP7 suppresses p53 in damaged alveolar epithelial cells while restoring...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $700,838 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning April 1, 2026 and concluding March 31, 2031. This award supports the development and optimization of advanced magnetic resonance (MR) imaging and treatment planning methodologies to enable functional avoidance stereotactic body radiation therapy (FA-SBRT) for...
- Federal Grant Award Summary The National Cancer Institute awarded a $648,049 Project Grant to the University of California, Irvine under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning April 2, 2026 and concluding March 31, 2031. Principal Investigator Shawn (Liangzhong) Xiang will develop protoacoustic imaging technology designed to enable real-time, three-dimensional mapping of the Bragg peak during proton therapy treatments. The project delivers a dual-modality...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $640,466 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2031. This five-year initiative focuses on developing a novel class of covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project involves designing and genetically incorporating latent...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $414,402 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. This research project develops multi-modality imaging and biomarker integration methods to improve glioblastoma radiation therapy targeting. The deliverables include: (1) white matter infiltrative risk maps derived from diffusion...